| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5826376 | Current Opinion in Pharmacology | 2013 | 7 Pages |
Abstract
⺠Peripheral and coronary artery disease has a high ischemic event rate despite antiplatelet therapy. ⺠Antiplatelet and anticoagulant agents inhibit different pathways of the coagulation pathway. ⺠Combination of antiplatelet agents with novel oral Factor II or Factor X inhibitors may reduce ischemic events. ⺠Combined antithrombotic therapy must carefully be tested for antithrombotic benefits and bleeding risk.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Vincenzo Jacomella, Natascia Corti, Marc Husmann,